Toxicity profile of polyradiomodification therapy used in the combination treatment for rectal cancer
Objective: to analyze the spectrum of toxic reactions associated with various polyradiomodification regimens used in the combination therapy for rectal cancer.Materials and methods. We have conducted a retrospective analysis of the data from a prospectively collected database. We included patients w...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
“ABV-press” Publishing house”, LLC
2018-11-01
|
| Series: | Тазовая хирургия и онкология |
| Subjects: | |
| Online Access: | https://ok.abvpress.ru/jour/article/view/256 |
| _version_ | 1797757057335558144 |
|---|---|
| author | Yu. A. Barsukov O. A. Vlasov S. I. Tkachev S. S. Gordeev |
| author_facet | Yu. A. Barsukov O. A. Vlasov S. I. Tkachev S. S. Gordeev |
| author_sort | Yu. A. Barsukov |
| collection | DOAJ |
| description | Objective: to analyze the spectrum of toxic reactions associated with various polyradiomodification regimens used in the combination therapy for rectal cancer.Materials and methods. We have conducted a retrospective analysis of the data from a prospectively collected database. We included patients with stages сT2–3N0M0 and сT2–3N1–2M0 resectable rectal cancer. Polyradiomodification regimens included a course of radiotherapy (5 × 5 Gy) with the following radiomodifiers: rectal administration of a biopolymer composition containing metronidazole (MZ) at a dose of 10 g/m2 (twice), intracavitary local microwave hyperthermia (three times on days 3–5) and oral capecitabine (Cap).Results. The study included 241 participants. Toxic reactions were observed in less than 33.2 % of patients receiving polyradiomodification as a part of combination therapy. The most common adverse events were gastrointestinal toxicity and neurotoxicity, diagnosed in 28.6 % and 17.4 % of cases respectively. The frequency of toxic reactions was significantly higher in patients receiving Cap14 + MZ regimen than in those receiving Cap5 + MZ regimen (p = 0.0038). However, the inclusion of microwave hyperthermia in both Cap5 and Cap14 therapeutic regimens had no impact on the frequency of toxic reactions (44.2 and 31.5 % respectively, p = 0.146). The proportion of patients with grade III gastrointestinal toxicity did not significantly vary across the groups (p = 0.16).Conclusion. The course of polyradiomodification included into the combination therapy for rectal cancer has an acceptable toxicity profile and can be used to improve long-term outcomes of combination treatment for rectal cancer. |
| first_indexed | 2024-03-12T18:09:33Z |
| format | Article |
| id | doaj.art-a127e11a85904fa2ae3dbeacdc376607 |
| institution | Directory Open Access Journal |
| issn | 2686-9594 |
| language | Russian |
| last_indexed | 2024-03-12T18:09:33Z |
| publishDate | 2018-11-01 |
| publisher | “ABV-press” Publishing house”, LLC |
| record_format | Article |
| series | Тазовая хирургия и онкология |
| spelling | doaj.art-a127e11a85904fa2ae3dbeacdc3766072023-08-02T09:16:31Zrus“ABV-press” Publishing house”, LLCТазовая хирургия и онкология2686-95942018-11-0183172510.17650/2220-3478-2018-8-3-17-25224Toxicity profile of polyradiomodification therapy used in the combination treatment for rectal cancerYu. A. Barsukov0O. A. Vlasov1S. I. Tkachev2S. S. Gordeev3N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaObjective: to analyze the spectrum of toxic reactions associated with various polyradiomodification regimens used in the combination therapy for rectal cancer.Materials and methods. We have conducted a retrospective analysis of the data from a prospectively collected database. We included patients with stages сT2–3N0M0 and сT2–3N1–2M0 resectable rectal cancer. Polyradiomodification regimens included a course of radiotherapy (5 × 5 Gy) with the following radiomodifiers: rectal administration of a biopolymer composition containing metronidazole (MZ) at a dose of 10 g/m2 (twice), intracavitary local microwave hyperthermia (three times on days 3–5) and oral capecitabine (Cap).Results. The study included 241 participants. Toxic reactions were observed in less than 33.2 % of patients receiving polyradiomodification as a part of combination therapy. The most common adverse events were gastrointestinal toxicity and neurotoxicity, diagnosed in 28.6 % and 17.4 % of cases respectively. The frequency of toxic reactions was significantly higher in patients receiving Cap14 + MZ regimen than in those receiving Cap5 + MZ regimen (p = 0.0038). However, the inclusion of microwave hyperthermia in both Cap5 and Cap14 therapeutic regimens had no impact on the frequency of toxic reactions (44.2 and 31.5 % respectively, p = 0.146). The proportion of patients with grade III gastrointestinal toxicity did not significantly vary across the groups (p = 0.16).Conclusion. The course of polyradiomodification included into the combination therapy for rectal cancer has an acceptable toxicity profile and can be used to improve long-term outcomes of combination treatment for rectal cancer.https://ok.abvpress.ru/jour/article/view/256rectal cancercombination therapypolyradiomodificationtoxicity |
| spellingShingle | Yu. A. Barsukov O. A. Vlasov S. I. Tkachev S. S. Gordeev Toxicity profile of polyradiomodification therapy used in the combination treatment for rectal cancer Тазовая хирургия и онкология rectal cancer combination therapy polyradiomodification toxicity |
| title | Toxicity profile of polyradiomodification therapy used in the combination treatment for rectal cancer |
| title_full | Toxicity profile of polyradiomodification therapy used in the combination treatment for rectal cancer |
| title_fullStr | Toxicity profile of polyradiomodification therapy used in the combination treatment for rectal cancer |
| title_full_unstemmed | Toxicity profile of polyradiomodification therapy used in the combination treatment for rectal cancer |
| title_short | Toxicity profile of polyradiomodification therapy used in the combination treatment for rectal cancer |
| title_sort | toxicity profile of polyradiomodification therapy used in the combination treatment for rectal cancer |
| topic | rectal cancer combination therapy polyradiomodification toxicity |
| url | https://ok.abvpress.ru/jour/article/view/256 |
| work_keys_str_mv | AT yuabarsukov toxicityprofileofpolyradiomodificationtherapyusedinthecombinationtreatmentforrectalcancer AT oavlasov toxicityprofileofpolyradiomodificationtherapyusedinthecombinationtreatmentforrectalcancer AT sitkachev toxicityprofileofpolyradiomodificationtherapyusedinthecombinationtreatmentforrectalcancer AT ssgordeev toxicityprofileofpolyradiomodificationtherapyusedinthecombinationtreatmentforrectalcancer |